Biosensors that measure glucose are now available without a prescription. Wearing one burst my wellness bubble in ways I wasn ...

The FDA cleared Eversense 365 as the first 1-year integrated continuous glucose monitoring (CGM) system for adults with type ...

Senseonics Holdings, Inc. SENS, along with Ascensia Diabetes Care, announced the receipt of the FDA’s clearance for the ...

Remote patient monitoring has exploded since the pandemic. In just four years from the beginning of 2019 through 2022, ...

Continuous glucose monitoring, compared with fingerstick tests, was feasible and accurate in an inpatient setting among patients and nurses.

Nearly 40 million Americans have diabetes, and nearly half of those are people who have Type 2 diabetes and are aged 65 or older. This population has a higher risk of ...

DexCom's revised FY24 sales guidance in the Q2 earnings call led to a $18bn valuation reset. Read why I think DXCM stock is a ...

If a patient receives a continuous glucose monitor device through their medical benefit, they may be more adherent and may ...

These devices are increasingly popular in diabetes management and health monitoring. As previously announced, Trinity Biotech has entered into a non-binding Letter of Intent with Bayer for the launch ...

Eversense 365 is said to be the world's first one-year CGM system, offering a new long-term solution for diabetes management.

Their research has been published in Science Advances, titled "Coin-sized, fully integrated, and minimally invasive ...

The U.S. FDA cleared Senseonic Holdings Inc.’s Eversense 365, the first continuous glucose monitor to last a full year with a single sensor rather than the 10 days to two weeks typical for wearable ...